Company news
Cynata Therapeutics Limited (ASX:CYP) news
Cynata Therapeutics Limited news releases on 6ix. Latest, Jul 30, 2020: Cynata Announces Positive Results from GvHD Trial Follow-up
Press releases — page 3
Cynata Announces Positive Results from GvHD Trial Follow-up
July 30, 2020
Ethics Approval & Expedited Pathway for Phase 3 OA Trial
June 17, 2020
Block Trade Proceeds to Reduce Director Loans
June 16, 2020
Cynata Successfully Completes Share Purchase Plan
May 26, 2020
Ethics Approval to Commence Clinical Trial in COVID-19
May 7, 2020
Share Purchase Plan Booklet
April 30, 2020
Cynata announces $5.55m capital raising
April 22, 2020
Cynata MSCs beneficial in preclinical ARDS study
April 17, 2020
Cynata provides guidance on planned clinical trials
April 1, 2020
Market Update & Additional A$618k R&D Tax Refund
March 10, 2020
Notice of Allowance from Israel Patent Office
February 6, 2020
December 2019 Quarterly Report
January 29, 2020
Cynata Therapeutics : UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
January 14, 2020
Cynata Receives UK Regulatory Approval for CLI Trial
January 13, 2020
Cynata Receives $1.892m R&D Tax Incentive Refund
January 6, 2020
Cymerus MSCs Effective in Preclinical Model of Sepsis
December 4, 2019
CYP Files Application to Commence Phase 2 CLI Clinical Trial
November 24, 2019
Cynata Awarded Grant for Coronary Artery Disease Study
October 27, 2019
Notice of Allowance from CIPO for Patent Application
October 24, 2019
September 2019 Quarterly Report
October 23, 2019
Cynata & Sumitomo Withdraw from Acquisition Discussions
October 16, 2019
CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial
October 2, 2019
Cynata Receives US$3 million Fujifilm License Fee
September 25, 2019
Fujifilm Exercises License Option in GvHD
September 17, 2019
Update on Discussions with Sumitomo and Fujifilm
August 14, 2019
Response to ASX Aware Query
July 24, 2019
Response to ASX Price and Volume Query
July 19, 2019
Cynata confirms receipt of indicative non-binding proposal
July 18, 2019
June 2019 Quarterly Report
July 4, 2019
Cynata Strengthens Board & Executive Management Team
May 19, 2019
March 2019 Quarterly Report
April 26, 2019
Cynata Extends FUJIFILM Licence Option in GvHD
March 20, 2019
Cynata Receives Favourable Advice on Planned CLI Trial
March 11, 2019
December 2018 Quarterly Report
January 29, 2019
CYP Receives Notice of Acceptance from Aust Patent Office
January 6, 2019
Cynata Completes Clinical Study Report for Phase 1 Trial of CYP-001 in GvHD
December 18, 2018
Cynata Completes Clinical Study Report in GvHD
December 17, 2018
NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus™ MSCs in Patients with Osteoarthritis
December 13, 2018
NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
December 12, 2018
Cynata Receives $1.3m R&D Tax Incentive Refund
November 18, 2018
CYP Receives Notice of Allowance from European Patent Office
November 6, 2018
September 2018 Quarterly Report
October 23, 2018
Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies
October 18, 2018
MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
October 17, 2018
Cynata MSCs Ameliorate CRS in Preclinical Study
September 19, 2018
Cynata Advances to Official Meeting with Japanese PMDA
September 2, 2018
Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
August 29, 2018
Appendix 4E & Financial Statements
August 22, 2018
Cymerus MSCs improve cardiac recovery in preclinical study
July 30, 2018
June 2018 Quarterly Report
July 11, 2018